Tumor necrosis factor-related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype

Molecular Biology of the Cell

Volumn 26, Issue 18, 2015, Pages 3178-3189

  Gao, Jing ^a   Wang, Dongsheng ^a   Liu, Dan ^a   Liu, Min ^a   Ge, Yehua ^a   Jiang, Minghong ^a   Liu, Yanxin ^a   Zheng, Dexian ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ANTIINFLAMMATORY AGENT; CYTOKINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICRORNA 146A; RECOMBINANT SOLUBLE TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; MICRORNA; MIRN146 MICRORNA, HUMAN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG CYTOTOXICITY; EMBRYO; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; INFLAMMATION; LUNG CANCER CELL LINE; MACROPHAGE FUNCTION; MALE; MOUSE; NCI H460 CELL LINE; NEGATIVE FEEDBACK; NONHUMAN; PERITONEUM MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; NUDE MOUSE; TRANSCRIPTION INITIATION;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CYTOKINES; DOWN-REGULATION; HISTONE DEACETYLASES; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICRORNAS; NF-KAPPA B; PHENOTYPE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84942156017     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E15-04-0209     Document Type: Article

References (75)

1. Allavena P, Sica A, Solinas G, Porta C, Mantovani A (2008). The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66, 1-9.
2. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104, 155-162.
3. Auffray C, Sieweke MH, Geissmann F (2009). Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27, 669-692.
4. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
5. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. (2011). CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616.
6. Bi Y, Liu G, Yang R (2009). MicroRNAs: novel regulators during the immune response. J Cell Physiol 218, 467-472.
7. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J (2000). TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2, 241-243.
8. Brost S, Koschny R, Sykora J, Stremmel W, Lasitschka F, Walczak H, Ganten TM (2010). Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. Pathol Res Practice 206, 43-50.
9. Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai le M, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A (2006). The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 119, 944-954.
10. Calao M, Burny A, Quivy V, Dekoninck A, Van Lint C (2008). A pervasive role of histone acetyltransferases and deacetylases in an NF-κB-signaling code. Trends Biochem Sci 33, 339-349.
11. Cameron JE, Yin Q, Fewell C, Lacey M, McBride J, Wang X, Lin Z, Schaefer BC, Flemington EK (2008). Epstein-Barr virus latent membrane protein 1 induces cellular microRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol 82, 1946-1958.
12. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L (1997). Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7, 821-830.
13. Chen X, Barozzi I, Termanini A, Prosperini E, Recchiuti A, Dalli J, Mietton F, Matteoli G, Hiebert S, Natoli G (2012). Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci USA 109, E2865-E2874.
14. Cretney E, Takeda K, Smyth MJ (2007). Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 39, 280-286.
15. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370, 737-749.
16. Diao Z, Shi J, Zhu J, Yuan H, Ru Q, Liu S, Liu Y, Zheng D (2013). TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+ CD25+ Treg apoptosis. Cancer Immunol Immunother 62, 653-663.
17. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P (2009). Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer 125, 367-373.
18. Earel JK Jr, VanOosten RL, Griffith TS (2006). Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosisinducing ligand-resistant bladder tumor cells. Cancer Res 66, 499-507.
19. Elsharkawy AM, Oakley F, Lin F, Packham G, Mann DA, Mann J (2010). The NF-κB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes. J Hepatol 53, 519-527.
20. Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, et al. (2015). CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res 75, 950-962.
21. Fanger NA, Maliszewski CR, Schooley K, Griffith TS (1999). Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190, 1155-1164.
22. Fujii K, Fujii Y, Hubscher S, Tanaka Y (2001). CD44 is the physiological trigger of Fas up-regulation on rheumatoid synovial cells. J Immunol 167, 1198-1203.
23. Gang H, Shaw J, Dhingra R, Davie JR, Kirshenbaum LA (2013). Epigenetic regulation of canonical TNFα pathway by HDAC1 determines survival of cardiac myocytes. Am J Physiol Heart Circ Physiol 304, H1662-1669.
24. Gordon S (2003). Alternative activation of macrophages. Nat Rev Immunol 3, 23-35.
25. Gordon S, Taylor PR (2005). Monocyte and macrophage heterogeneity. Nat Rev Immunol 5, 953-964.
26. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA (1999). Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189, 1343-1354.
27. Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, Lovelace E, Reid RC, Le GT, Hume DA, et al. (2010). Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukocyte Biol 87, 1103-1114.
28. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM (2012). Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012, 948098.
29. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, et al. (2010). Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28, 2839-2846.
30. Hofbauer LC, Schoppet M, Christ M, Teichmann J, Lange U (2006). Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology 45, 1218-1222.
31. Hoffmann O, Priller J, Prozorovski T, Schulze-Topphoff U, Baeva N, Lunemann JD, Aktas O, Mahrhofer C, Stricker S, Zipp F, et al. (2007). TRAIL limits excessive host immune responses in bacterial meningitis. J Clin Invest 117, 2004-2013.
32. Janzer A, Lim S, Fronhoffs F, Niazy N, Buettner R, Kirfel J (2012). Lysinespecific demethylase 1 (LSD1) and histone deacetylase 1 (HDAC1) synergistically repress proinflammatory cytokines and classical complement pathway components. Biochem Biophys Res Commun 421, 665-670.
33. Jiang M, Xiang Y, Wang D, Gao J, Liu D, Liu Y, Liu S, Zheng D (2012). Dysregulated expression of miR-146a contributes to age-related dysfunction of macrophages. Aging Cell 11, 29-40.
34. Kuo PL, Shen KH, Hung SH, Hsu YL (2012). CXCL1/GROalpha increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-κB/HDAC1 epigenetic regulation. Carcinogenesis 33, 2477-2487.
35. Li B, Vincent A, Cates J, Brantley-Sieders DM, Polk DB, Young PP (2009). Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res 69, 338-348.
36. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25, 402-408.
37. Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M (2005). Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 64, 854-858.
38. Lukiw WJ, Zhao Y, Cui JG (2008). An NF-κB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 283, 31315-31322.
39. Ma H, Liu Y, Liu S, Kung HF, Sun X, Zheng D, Xu R (2005a). Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int J Cancer 116, 314-321.
40. Ma H, Liu Y, Liu S, Xu R, Zheng D (2005b). Oral adeno-associated virussTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 42, 1355-1363.
41. Mantovani A, Allavena P (2015). The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 212, 435-445.
42. Minucci S, Pelicci PG (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 38-51.
43. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839-843.
44. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997). The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113.
45. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271, 12687-12690.
46. Qian BZ, Pollard JW (2010). Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51.
47. Quivy V, Van Lint C (2004). Regulation at multiple levels of NF-κB-mediated transactivation by protein acetylation. Biochem Pharmacol 68, 1221-1229.
48. Rebane A, Akdis CA (2013). MicroRNAs: essential players in the regulation of inflammation. J Allergy Clin Immunol 132, 15-26.
49. Rhee JW, Lee KW, Sohn WJ, Lee Y, Jeon OH, Kwon HJ, Kim DS (2007). Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappa B in response to CpG-oligodeoxynucleotides in RAW 264.7 cells. Mol Immunol 44, 1393-1400.
50. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et al. (2011). HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19, 31-44.
51. Ruffell B, Coussens LM (2015). Macrophages and therapeutic resistance in cancer. Cancer Cell 27, 462-472.
52. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ (2011). Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 32, 335-343.
53. Shakespear MR, Hohenhaus DM, Kelly GM, Kamal NA, Gupta P, Labzin LI, Schroder K, Garceau V, Barbero S, Iyer A, et al. (2013). Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages. J Biol Chem 288, 25362-25374.
54. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, et al. (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821.
55. Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F, Xu R (2005). Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 65, 1687-1692.
56. Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, Scheerer M, Roberts LR, Molina J, Shridhar V (2007). Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 26, 4969-4978.
57. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006). NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103, 12481-12486.
58. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB (2006). Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281, 5612-5622.
59. Tang W, Wang W, Zhang Y, Liu S, Liu Y, Zheng D (2009a). TRAIL receptor mediates inflammatory cytokine release in an NF-κB-dependent manner. Cell Res 19, 758-767.
60. Tang W, Wang W, Zhang Y, Liu S, Liu Y, Zheng D (2009b). Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. FEBS J 276, 581-593.
61. Traves PG, Luque A, Hortelano S (2012). Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm 2012, 568783.
62. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, et al. (1997). TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16, 5386-5397.
63. Wang D, Liu D, Gao J, Liu M, Liu S, Jiang M, Liu Y, Zheng D (2013a). TRAILinduced miR-146a expression suppresses CXCR4-mediated human breast cancer migration. FEBS J 280, 3340-3353.
64. Wang JH, Shih KS, Wu YW, Wang AW, Yang CR (2013b). Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1beta signaling in osteoarthritis fibroblastlike synoviocytes. Osteoarthritis Cartilage 21, 1987-1996.
65. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682.
66. Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA (2008). Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans 36, 1211-1215.
67. Woo SM, Choi YK, Cho SG, Park S, Ko SG (2013). A new herbal formula, KSG-002, suppresses breast cancer growth and metastasis by targeting NF-κB-dependent TNF alpha production in macrophages. Evid Based Complement Alternat Med 2013, 728258.
68. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, et al. (2006). TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103, 10397-10402.
69. Yang XJ, Seto E (2007). HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26, 5310-5318.
70. Yin L, Laevsky G, Giardina C (2001). Butyrate suppression of colonocyte NF-κB activation and cellular proteasome activity. J Biol Chem 276, 44641-44646.
71. Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E, et al. (2012). Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 31, 3002-3008.
72. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P (2000). Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482, 193-199.
73. Zhao Y, Samal E, Srivastava D (2005). Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436, 214-220.
74. Zhong H, May MJ, Jimi E, Ghosh S (2002). The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9, 625-636.
75. Zhou R, Gong AY, Chen D, Miller RE, Eischeid AN, Chen XM (2013). Histone deacetylases and NF-kB signaling coordinate expression of CX3CL1 in epithelial cells in response to microbial challenge by suppressing miR-424 and miR-503. PloS One 8, e65153.